[go: up one dir, main page]

FI964592L - Papilloomavirusrokotteita - Google Patents

Papilloomavirusrokotteita Download PDF

Info

Publication number
FI964592L
FI964592L FI964592A FI964592A FI964592L FI 964592 L FI964592 L FI 964592L FI 964592 A FI964592 A FI 964592A FI 964592 A FI964592 A FI 964592A FI 964592 L FI964592 L FI 964592L
Authority
FI
Finland
Prior art keywords
papillomavirus vaccines
papillomavirus
vaccines
Prior art date
Application number
FI964592A
Other languages
English (en)
Swedish (sv)
Other versions
FI119815B (fi
FI964592A0 (fi
Inventor
Kathrin U Jansen
James C Cook
Hugh A George
Kathryn J Hofman
Joseph G Joyce
Ernest Dale Lehman
Henry Z Markus
Mark Rosolowsky
Loren D Schultz
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI964592L publication Critical patent/FI964592L/fi
Publication of FI964592A0 publication Critical patent/FI964592A0/fi
Application granted granted Critical
Publication of FI119815B publication Critical patent/FI119815B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
FI964592A 1994-05-16 1996-11-15 Papilloomavirusproteiinin valmistusmenetelmä FI119815B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24279494A 1994-05-16 1994-05-16
US24279494 1994-05-16
US9506006 1995-05-15
PCT/US1995/006006 WO1995031532A1 (en) 1994-05-16 1995-05-15 Papillomavirus vaccines

Publications (3)

Publication Number Publication Date
FI964592L true FI964592L (fi) 1996-11-15
FI964592A0 FI964592A0 (fi) 1996-11-15
FI119815B FI119815B (fi) 2009-03-31

Family

ID=22916213

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964592A FI119815B (fi) 1994-05-16 1996-11-15 Papilloomavirusproteiinin valmistusmenetelmä

Country Status (24)

Country Link
EP (1) EP0757717B1 (fi)
JP (1) JP3863559B2 (fi)
CN (1) CN1152935A (fi)
AT (1) ATE328068T1 (fi)
AU (1) AU693203B2 (fi)
BG (1) BG100974A (fi)
BR (1) BR9507657A (fi)
CA (1) CA2189882C (fi)
CZ (1) CZ336696A3 (fi)
DE (1) DE69535018T2 (fi)
DK (1) DK0757717T3 (fi)
ES (1) ES2264126T3 (fi)
FI (1) FI119815B (fi)
HU (1) HUT76354A (fi)
MX (1) MXPA96005662A (fi)
NO (1) NO322133B1 (fi)
NZ (1) NZ285941A (fi)
PL (1) PL183781B1 (fi)
PT (1) PT757717E (fi)
RO (1) RO117541B1 (fi)
RU (1) RU2206608C2 (fi)
SI (1) SI0757717T1 (fi)
SK (1) SK147696A3 (fi)
WO (1) WO1995031532A1 (fi)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AU694269B2 (en) * 1994-09-22 1998-07-16 Merck Sharp & Dohme Corp. Dna encoding human papillomavirus type 6a
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
PL347472A1 (en) 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
CN100406060C (zh) 1998-10-16 2008-07-30 史密丝克莱恩比彻姆生物有限公司 一种佐剂组合物
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
DE60040727D1 (de) 1999-02-05 2008-12-18 Merck & Co Inc Menschliche papillomavirus impfstoff-formulierungen
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1501921B2 (en) 2002-04-30 2012-07-25 Oncolytics Biotech Inc. Improved viral purification methods
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
UA112529C2 (uk) * 2004-09-30 2016-09-26 Байер Хелскеа Елелсі Пристрій та процес інтегрованого безперервного виробництва біологічних молекул
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
PL2601970T3 (pl) 2006-09-29 2017-07-31 Takeda Vaccines, Inc. Preparaty szczepionki przeciw norowirusowi
PL2118292T3 (pl) * 2007-01-30 2011-12-30 Transgene Sa Polipeptyd E2 wirusa brodawczaka stosowany do szczepienia
AU2008224877B2 (en) 2007-03-14 2013-07-11 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
MX2009014246A (es) 2007-06-26 2010-03-31 Japan Health Science Found Antigeno de vacuna con la capacidad de inducir anticuerpo de neutralizacion y reaccion cruzada contra virus de papiloma humano del tipo de alto riesgo.
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
MY162658A (en) * 2007-11-23 2017-06-30 Shanghai Zerun Biotechnology Co Ltd Genes encoding major capsid protein l1 of human papilloma virus and use of the same
KR102118458B1 (ko) * 2008-08-08 2020-06-03 다케다 백신즈 인코포레이티드 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들
RU2377305C1 (ru) * 2008-11-13 2009-12-27 Всеволод Иванович Киселев Мукозальная вакцина для иммунотерапии заболеваний, обусловленных вирусами папилломы человека, и способ лечения с ее использованием (варианты)
AU2009348078B2 (en) * 2009-06-19 2013-03-14 Eyegene Inc. Vaccine for cervical cancer
CN102234661A (zh) * 2010-04-23 2011-11-09 北京生物制品研究所 人乳头瘤病毒类病毒颗粒的制备方法和外源蛋白表达盒、表达系统
EA201390812A1 (ru) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. Лиофилизированные вирусные составы
MX350932B (es) 2010-12-02 2017-09-26 Oncolytics Biotech Inc Formulaciones virales liquidas.
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
US20120273424A1 (en) * 2011-04-29 2012-11-01 Oncolytics Biotech Inc. Methods of purifying viruses using gel permeation chromatography
MX356586B (es) 2011-07-11 2018-06-05 Takeda Vaccines Inc Formulaciones parenterales de vacunas contra los norovirus.
SG11201401579UA (en) * 2011-12-01 2014-07-30 Univ Cape Town Hpv chimaeric particle
CN103215302B (zh) * 2012-01-21 2019-01-15 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN103361377B (zh) * 2012-03-28 2017-12-05 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv6 l1蛋白的方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110592133A (zh) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CN104673760B (zh) * 2013-11-29 2018-01-02 南京赛威信生物医药有限公司 一种原核细胞表达类病毒颗粒的纯化方法
RU2546241C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 16
RU2546243C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики папилломавирусной инфекции человека и способ ее получения
RU2546242C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 18
RU2546240C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 56
EA201790944A1 (ru) * 2014-12-26 2017-11-30 Айджин, Инк. Способ получения вирусоподобных частиц папилломавируса человека
BR112018004400A2 (pt) * 2015-09-04 2018-12-04 Inventprise Llc composições de vacina vlp estabilizadas
RU2676160C1 (ru) * 2018-02-14 2018-12-26 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей Hansenula polymorpha - продуцент главного капсидного белка L1 вируса папилломы человека типа 11
RU2681174C1 (ru) * 2018-07-12 2019-03-04 Закрытое акционерное общество научно-производственная компания "Комбиотех" Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина
KR102767403B1 (ko) 2019-07-19 2025-02-14 사이노셀테크 엘티디. 키메라 유두종바이러스 l1 단백질
CN116426396B (zh) * 2023-06-09 2023-09-01 内蒙古工业大学 一株耐硫酸铵酿酒酵母及其筛选方法
DE102024106741B4 (de) * 2024-03-08 2025-10-09 Schott Ag Mikroarrays mit Nitrozellulosebeschichtung und Herstellungsverfahren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586428B1 (fr) * 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
DE3625257A1 (de) * 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
EP1471147A3 (en) * 1991-07-19 2007-03-21 The University Of Queensland Method of making a recombinant molecule for the expression of HPV-16 L1 protein
DE122007000100I1 (de) * 1992-06-25 2008-03-27 Papillomavirus vakzine
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product

Also Published As

Publication number Publication date
BG100974A (en) 1998-04-30
NZ285941A (en) 1998-05-27
MXPA96005662A (es) 2004-08-19
HUT76354A (en) 1997-08-28
PL183781B1 (pl) 2002-07-31
CZ336696A3 (en) 1997-07-16
BR9507657A (pt) 1997-09-09
NO964862D0 (no) 1996-11-15
ATE328068T1 (de) 2006-06-15
FI119815B (fi) 2009-03-31
SK147696A3 (en) 1997-08-06
RO117541B1 (ro) 2002-04-30
RU2206608C2 (ru) 2003-06-20
HU9603155D0 (en) 1997-01-28
EP0757717A4 (en) 1998-04-15
AU693203B2 (en) 1998-06-25
PL317234A1 (en) 1997-03-17
CA2189882A1 (en) 1995-11-23
CN1152935A (zh) 1997-06-25
NO322133B1 (no) 2006-08-21
PT757717E (pt) 2006-09-29
JP3863559B2 (ja) 2006-12-27
DE69535018D1 (de) 2006-07-06
JPH10500847A (ja) 1998-01-27
CA2189882C (en) 2005-09-20
WO1995031532A1 (en) 1995-11-23
DE69535018T2 (de) 2007-02-15
SI0757717T1 (sl) 2006-08-31
EP0757717B1 (en) 2006-05-31
DK0757717T3 (da) 2006-09-25
ES2264126T3 (es) 2006-12-16
FI964592A0 (fi) 1996-11-15
EP0757717A1 (en) 1997-02-12
AU2549595A (en) 1995-12-05
NO964862L (no) 1997-01-16

Similar Documents

Publication Publication Date Title
FI964592L (fi) Papilloomavirusrokotteita
FI965224A7 (fi) Polynukleotidirokote papilloomavirukselle
BR9711853A (pt) Vacinas
KR970704468A (ko) 폴리에피토프 백신(polyepitope vaccines)
NO20003302D0 (no) Vaksine
ATE209045T1 (de) Hepatitis b impfstoff
BR9609258A (pt) Vacinas contra hepatite c
CY2007015I1 (el) Εμβολιο ιου θηλωματος
NO20006191D0 (no) Vaksine
GB9410922D0 (en) Vaccines
FI972030A7 (fi) Puhdistettuja papillomavirusproteiineja
GB9420146D0 (en) Papillomavirus vaccine
EP0967993A4 (en) ANTI-COCAINE VACCINE
FI952629L (fi) Kefiksiimivalmiste
DE69509766D1 (de) Mikroemulsionen
NO20005599L (no) Vaksine
FR2715304B1 (fr) Vaccin anti-allergique.
DE69530008D1 (de) Bodenverdichtung
KR970703417A (ko) 유두종 바이러스 백신(Papillomavirus vaccines)
KR960009867U (ko) 분리식 제기
GB9406708D0 (en) Vaccines
ATE196239T1 (de) Cervicalorthese
SE9403012D0 (sv) Preparation
KR960019939U (ko) 제기
SE9403065D0 (sv) Hållaranordning

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119815

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: MERCK SHARP & DOHME CORP.

Free format text: MERCK SHARP & DOHME CORP.

MA Patent expired